Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.

@article{Zhao2015CombinationTW,
  title={Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.},
  author={Yong Zhao and Mei-juan Tu and Yi-Feng Yu and Wei-peng Wang and Qiu-xia Chen and Jing-xin Qiu and Aixi Yu and A. -Reum Yu},
  journal={Biochemical pharmacology},
  year={2015},
  volume={98 4},
  pages={602-13}
}
Osteosarcoma (OS) is the most common form of primary malignant bone tumor and prevalent among children and young adults. Recently we have established a novel approach to bioengineering large quantity of microRNA-34a (miR-34a) prodrug for miRNA replacement therapy. This study is to evaluate combination treatment with miR-34a prodrug and doxorubicin, which may synergistically suppress human OS cell growth via RNA interference and DNA intercalation. Synergistic effects were indeed obvious between… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…